phenyloxazol-2-yl)benzene] (POPOP).

The competition experiments with liver microsomal fraction, using $^3$H-Tam as the reference ligand, were performed according to the previously reported procedure.[21] The liver microsomal fractions were first incubated at 4 °C for 2 h, with 2 μM diethylstibestrol added in a small volume of DMF to saturate ER sites. Aliquots (200 μL) of the fraction were then mixed in a Pyrex glass tube with 20 μL of competitor ($1 \times 10^{-9}$ M to $3 \times 10^{-6}$ M) and 20 μL of $^3$H-Tam ($1 \times 10^{-9}$ M) dissolved in 35% DMF–TEA buffer. The tubes were incubated for 18 h at 4 °C and then treated with charcoal–dextran slurry (100 μL) for 15 min at 4 °C to separate bound and free $^3$H-Tam. The tubes were centrifuged at 1000*g* for 15 min, and the supernatants were counted for radio activity.

**Uterotrophic and Antiuterotrophic Activity.** For uterotrophic activity various doses of the test compounds, suspended in 0.1 mL of propylene glycol–0.9% saline (1:1, v/v), were injected subcutaneously to the test animals on three consecutive days, while the control group of animals received the vehicle alone. Antiuterotrophic assay was similarly performed by administering various doses of test compounds and 0.3 μg of $E_2$ in the case of rats and 0.1 μg of $E_2$ in the case of mice, each suspended in 0.1 mL of propylene glycol–0.9% saline (1:1, v/v), to the test animals at two different sites, while the control group of animals received the injection of $E_2$ and the vehicle alone. Animals were autopsied 24 h after last injection and their uterine wet weights were recorded in the usual manner.

**Acknowledgment.** We acknowledge Dr. Nitya Anand for his keen interest in this study. We are grateful to Dr. A. H. Todd of ICI Ltd., U.K. for providing a gift sample of tamoxifen and to Dr. William R. Fields, of Eli Lilly, for providing samples of trioxifen and LY-11018. We would also like to acknowledge the Department of Science and Technology, Government of India, for financial support in carrying out the AEBS affinity studies, which were undertaken at IIT, Bombay.

# *Additions and Corrections*

**Volume 33, 1990**

**Manfred Reiffen,* Wolfgang Eberlein, Peter Müller, Manfred Psiorz, Klaus Noll, Joachim Heider, Christian Lillie, Walter Kobinger, and Peter Luger**: Specific Bradycardic Agents. 1. Chemistry, Pharmacology, and Structure–Activity Relationships of Substituted Benzazepinones, a New Class of Compounds Exerting Antiischemic Properties.

Page 1496. The correct contribution line should read as follows: Department of Chemical Research, Dr. Karl Thomae GmbH, Postfach 1755, D-7950 Biberach 1, West Germany, Department of Pharmacology, Ernst-Boehringer-Institut für Arzneimittelforschung, Dr. Boehringer-Gasse 5-11, A-1121 Wien, Austria, and Freie Universität Berlin, Institut für Kristallographie, Takustra ;se 6, 1000 Berlin 33, West Germany.

**P. S. Portoghese,* M. Sultana, and A. E. Takemori**: Design of Peptidomimetic δ Opioid Receptor Antagonists Using the Message–Address Concept.

Page 1714. In Table III, the δ $K_i$ (SE) value for compound **20** (OMI) should read 1.5 (0.4–5.1).